Response to Editor: Commentary on "Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma"

被引：0
|
作者：
Chen, Qin [1 ,2 ,3 ]
Wang, Xinyue [1 ,2 ]
Jiang, Richeng [1 ,2 ,4 ,5 ]
机构：
[1] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Tianjin Lung Canc Ctr, Dept Thorac Oncol, Tianjin, Peoples R China
[2] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjin Chest Hosp, Dept Resp & Crit Med, Tianjin, Peoples R China
[4] Tianjin Canc Hosp, Airport Hosp, Canc Precise Diag Ctr, Tianjin, Peoples R China
[5] Tianjin Med Univ Canc Inst & Hosp, Ctr Precis Canc Med & Translat Res, Tianjin, Peoples R China
来源：
CLINICAL LUNG CANCER | 2024年 / 25卷 / 08期
基金：
中国国家自然科学基金;
关键词：
THERAPY; MECHANISM;
D O I：
10.1016/j.clc.2024.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e479 / e481
页数：3
相关论文
共 50 条
  • [21] Evaluating PD-L1 in Cytology to Determine Eligibility for Anti-PD-1/PD-L1 Immunotherapy in Patients with Head and Neck Squamous Cell Carcinoma
    Liu, Zhonghua
    Roy-Chowdhuri, Sinchita
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 246 - 247
  • [22] Evaluating PD-L1 in Cytology to Determine Eligibility for Anti-PD-1/PD-L1 Immunotherapy in Patients with Head and Neck Squamous Cell Carcinoma
    Liu, Zhonghua
    Roy-Chowdhuri, Sinchita
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 246 - 247
  • [23] Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors
    Antian Gao
    Xiao Pan
    Xudong Yang
    Zitong Lin
    Investigational New Drugs, 2021, 39 : 1132 - 1138
  • [24] Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification
    Tostes, Francinne T.
    Fernandes, Italo
    Segatelli, Vanderlei
    Callegaro, Donato
    Pestana, Roberto Carmagnani
    CLINICAL COLORECTAL CANCER, 2021, 20 (04) : 350 - 353
  • [25] PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
    Evrard, D.
    Hourseau, M.
    Couvelard, A.
    Paradis, V.
    Gauthier, H.
    Raymond, E.
    Halimi, C.
    Barry, B.
    Faivre, S.
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [26] Distinct prognostic values of PD-L1 and PD-1 in lung adenocarcinoma and squamous cell carcinoma patients
    Wang, S.
    Qu, X.
    Li, Z.
    Che, X.
    Cao, L.
    Hu, X.
    Xu, L.
    Hou, K.
    Fan, Y.
    Wen, T.
    Li, C.
    Liu, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 102 - 102
  • [27] Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Zang, Yuan-Sheng
    MEDICAL HYPOTHESES, 2018, 116 : 111 - 113
  • [28] PD-1 and PD-L1 staining patterns in cervical squamous cell carcinoma
    Hodeib, M.
    Lester, J.
    Laury, A.
    Cass, I.
    Rimel, B. J.
    Li, A. J.
    Karlan, B. Y.
    Walsh, C. S.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (01) : 210 - 210
  • [29] Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series
    Fernandez-Trujillo, Liliana
    Garcia-Robledo, Juan E.
    Zuniga-Restrepo, Valeria
    Sua, Luz F.
    RESPIRATORY MEDICINE CASE REPORTS, 2020, 30
  • [30] Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice
    Villaruz, Liza C.
    Hunter, Katerina Ancevski
    Kurland, Brenda F.
    Abberbock, Shira
    Herbst, Cameron
    Dacic, Sanja
    HISTOPATHOLOGY, 2019, 74 (02) : 269 - 275
12345